UTRECHT, The Netherlands – AM-Pharma B.V., an emerging leader focused on developing therapeutics for severe medical conditions, today announced that members of its senior management team are scheduled to participate in the following investor conferences: Cowen 42nd Annual Healthcare Conference on Wednesday, March 9, 2022. The Company will be conducting investor meetings, which can be […]
Utrecht, The Netherlands, January 26, 2022 – AM Pharma B.V., an emerging leader focused on developing therapeutics for severe medical conditions, today announced that its Chief Operating Officer, Juliane Bernholz, PhD, is among the authors of a recently published peer-reviewed article discussing the design and implementation of clinical trials for Acute Kidney Injury (AKI). With representation […]
Utrecht, The Netherlands, January 5, 2022 – AM-Pharma B.V., an emerging leader focused on developing therapeutics for severe medical conditions, today announced that Erik van den Berg, the Company’s Chief Executive Officer, and Lars Boesgaard, Chief Financial Officer, will participate in the following investor conferences: Kempen’s 40th Annual Life Sciences Virtual Crossover Conference on Thursday, January […]
Utrecht, The Netherlands, 3 November, 2021 – AM-Pharma B.V., an emerging leader focused on developing therapeutics for severe medical conditions, today announced the appointment of Alexander Bastian as Vice President Value & Market Access, effective immediately. Mr. Bastian joins the company with over 19 years of leadership in product launch and market access strategies from […]
Utrecht, The Netherlands, 15 September, 2021 – AM-Pharma B.V., an emerging leader focused on developing therapeutics for severe medical conditions, today announced the appointment of Lars R. Boesgaard as Chief Financial Officer (CFO), effective immediately. Mr. Boesgaard’s career spans 25 years and includes CFO roles at public and private companies, where he built experience with […]
AM-Pharma to receive EUR 20 million upfront payment, and EUR 30 million related to milestones prior to regulatory submission, and up to EUR 195 million upon submission, NHI price listing and sales milestone payments bringing the overall deal value to EUR 245 million. Kyowa Kirin gains exclusive rights to develop and commercialize ilofotase alfa in […]
Utrecht, The Netherlands, 6 July, 2021 – AM-Pharma B.V., an emerging leader focused on developing therapeutics for severe medical conditions, today announced the appointment of Mark Altmeyer, MBA, as Chairman of its Supervisory Board. Mr. Altmeyer is a highly successful biopharma executive with decades of relevant strategic, operational, and commercial experience. As Chairman of AM-Pharma’s […]
Utrecht, The Netherlands, 1 July 2021 – AM-Pharma B.V., an emerging leader focused on developing therapeutics for severe medical conditions, today announced the enrollment of the first patient in Japan as part of its ongoing global pivotal Phase III trial, called REVIVAL. The REVIVAL study is evaluating ilofotase alfa, the Company’s proprietary recombinant human alkaline phosphatase, for the treatment of […]
Utrecht, The Netherlands, 15 June 2021 – AM-Pharma B.V., an emerging leader focused on developing therapeutics for severe medical conditions, today announced the appointment of Martijn Negen, MSc, MBA, as Vice President for Commercial Strategy. Martijn Negen has over 20 years of experience in pharmaceutical, biotech and diagnostic companies. He joins AM-Pharma from Alexion Pharma, […]
– First patients with COVID-19 enrolled in the REVIVAL Phase III study – COVID-19 patients with sepsis-associated acute kidney injury will be included in an exploratory cohort in the pivotal trial enrolling up to 1,600 SA-AKI patients overall – RVO, an agency of the Dutch Ministry of Economic Affairs and Climate Policy, provides a loan […]
